Abstract
A test of the concept of chemical suppression
of ovarian function by cytotoxic drugs previously
reported (Anderson et al., 1978, Br. J.
Cancer, 37, 477) revealed no supportive evidence
from follicular and luteal-phase measurements
of plasma oestradiol (E2) in 6 premenopausal
women prescribed repeated 5-day courses of
melphalan after mastectomy for cancer. To
circumvent the difficulties of frequent repeated
blood sampling, 3 of these patients were studied
in greater depth.
| Original language | English |
|---|---|
| Pages (from-to) | 314-315 |
| Number of pages | 1 |
| Journal | British Journal of Cancer |
| Volume | 40 |
| Issue number | 2 |
| Publication status | Published - 1979 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- melphalan
- urinary estrogens
- mastectomy
Fingerprint
Dive into the research topics of 'Melphalan and urinary estrogens'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver